Kilitch Drugs (India) Limited (NSE:KILITCH)
India · Delayed Price · Currency is INR 197.44
-3.10 (-1.55%)
Nov 11, 2026, 2:45 PM IST
Kilitch Drugs (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,385 | 2,355 | 1,983 | 1,544 | 1,396 | 1,142 |
Other Revenue | -41.62 | -0 | - | - | - | - |
| 2,343 | 2,355 | 1,983 | 1,544 | 1,396 | 1,142 | |
Revenue Growth | 11.88% | 18.74% | 28.47% | 10.58% | 22.20% | 66.71% |
Cost of Revenue | 1,225 | 1,267 | 1,053 | 793.92 | 754.16 | 673.86 |
Gross Profit | 1,119 | 1,088 | 930.05 | 749.8 | 641.83 | 468.49 |
Selling, General & Admin | 383.06 | 357.08 | 312.74 | 239.66 | 231.58 | 117.14 |
Other Operating Expenses | 393.67 | 360.22 | 302.65 | 262.06 | 234.61 | 234.96 |
Operating Expenses | 836.63 | 745.11 | 638.07 | 526.78 | 493.27 | 368.33 |
Operating Income | 282.08 | 342.67 | 291.98 | 223.02 | 148.56 | 100.16 |
Interest Expense | -51.54 | -55.61 | -50.41 | -59.29 | -49.19 | -11.98 |
Interest & Investment Income | 5.47 | 5.47 | 36 | 4.2 | 3.1 | 2.5 |
Earnings From Equity Investments | 0.06 | 0.06 | -0 | -0.02 | 0.02 | -0.02 |
Currency Exchange Gain (Loss) | 59.84 | 59.84 | 28.07 | 19.96 | 15.6 | -2.29 |
Other Non Operating Income (Expenses) | 6.32 | 6.32 | 7.93 | 0.22 | 0.59 | 2.62 |
EBT Excluding Unusual Items | 302.23 | 358.74 | 313.57 | 188.09 | 118.69 | 90.98 |
Impairment of Goodwill | -8.43 | -8.43 | -8.43 | -8.43 | -8.43 | -8.43 |
Gain (Loss) on Sale of Investments | 36.23 | 36.23 | 39.6 | 13.89 | 9.88 | 13.59 |
Pretax Income | 330.03 | 386.54 | 344.74 | 193.55 | 120.14 | 96.14 |
Income Tax Expense | 104.25 | 91.54 | 95.34 | 57.79 | 37.32 | 34.01 |
Earnings From Continuing Operations | 225.78 | 295 | 249.4 | 135.75 | 82.83 | 62.14 |
Minority Interest in Earnings | 15.13 | 6.66 | 17.61 | 10.26 | 21.65 | 11.54 |
Net Income | 240.91 | 301.66 | 267.01 | 146.01 | 104.48 | 73.67 |
Net Income to Common | 240.91 | 301.66 | 267.01 | 146.01 | 104.48 | 73.67 |
Net Income Growth | -13.84% | 12.98% | 82.86% | 39.75% | 41.82% | 100.68% |
Shares Outstanding (Basic) | 35 | 34 | 16 | 32 | 31 | 31 |
Shares Outstanding (Diluted) | 35 | 34 | 16 | 32 | 31 | 31 |
Shares Change | 7.78% | 110.43% | -49.52% | 2.23% | 0.10% | 0.56% |
EPS (Basic) | 6.89 | 8.91 | 16.60 | 4.58 | 3.35 | 2.37 |
EPS (Diluted) | 6.88 | 8.91 | 16.60 | 4.58 | 3.35 | 2.36 |
EPS Growth | -20.09% | -46.33% | 262.19% | 36.71% | 41.76% | 99.58% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -341.29 | -755.5 | -293.31 | -79.85 | -12.26 | -24.19 |
Free Cash Flow Per Share | -9.76 | -22.32 | -18.24 | -2.51 | -0.39 | -0.78 |
Gross Margin | 47.74% | 46.20% | 46.90% | 48.57% | 45.98% | 41.01% |
Operating Margin | 12.04% | 14.55% | 14.72% | 14.45% | 10.64% | 8.77% |
Profit Margin | 10.28% | 12.81% | 13.46% | 9.46% | 7.48% | 6.45% |
Free Cash Flow Margin | -14.56% | -32.08% | -14.79% | -5.17% | -0.88% | -2.12% |
EBITDA | 340.21 | 368.71 | 312.97 | 247.01 | 175.51 | 116.29 |
EBITDA Margin | 14.52% | 15.66% | 15.78% | 16.00% | 12.57% | 10.18% |
D&A For EBITDA | 58.13 | 26.04 | 20.99 | 23.99 | 26.96 | 16.13 |
EBIT | 282.08 | 342.67 | 291.98 | 223.02 | 148.56 | 100.16 |
EBIT Margin | 12.04% | 14.55% | 14.72% | 14.45% | 10.64% | 8.77% |
Effective Tax Rate | 31.59% | 23.68% | 27.66% | 29.86% | 31.06% | 35.37% |
Revenue as Reported | 2,456 | 2,467 | 2,095 | 1,589 | 1,425 | 1,171 |